144 related articles for article (PubMed ID: 38701062)
1. Early therapy evaluation of intra-arterial trastuzumab injection in a human breast cancer xenograft model using multiparametric MR imaging.
Kim BK; Kim B; You SH; Jang MS; Im GH; Kim KH
PLoS One; 2024; 19(5):e0300171. PubMed ID: 38701062
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor.
Kim B; Kim K; Im KH; Kim JH; Lee JH; Jeon P; Byun H
J Neurooncol; 2016 Apr; 127(2):243-51. PubMed ID: 26746691
[TBL] [Abstract][Full Text] [Related]
3. Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer.
Barnes SL; Sorace AG; Loveless ME; Whisenant JG; Yankeelov TE
NMR Biomed; 2015 Oct; 28(10):1345-56. PubMed ID: 26332194
[TBL] [Abstract][Full Text] [Related]
4. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
[TBL] [Abstract][Full Text] [Related]
6. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
[TBL] [Abstract][Full Text] [Related]
7. Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer.
Syed AK; Woodall R; Whisenant JG; Yankeelov TE; Sorace AG
Neoplasia; 2019 Jan; 21(1):17-29. PubMed ID: 30472501
[TBL] [Abstract][Full Text] [Related]
8. [Preclinical application of MR and fluorescent dual-modality imaging combined with photothermal therapy in HER-2 positive breast cancer].
Luo XJ; Li J; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):587-593. PubMed ID: 30139028
[No Abstract] [Full Text] [Related]
9. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
[TBL] [Abstract][Full Text] [Related]
10. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
[TBL] [Abstract][Full Text] [Related]
11. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract][Full Text] [Related]
12. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
13. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
[TBL] [Abstract][Full Text] [Related]
14. MRI evaluation of the effects of whole brain radiotherapy on breast cancer brain metastasis.
Crowe W; Wang L; Zhang Z; Varagic J; Bourland JD; Chan MD; Habib AA; Zhao D
Int J Radiat Biol; 2019 Mar; 95(3):338-346. PubMed ID: 30499763
[TBL] [Abstract][Full Text] [Related]
15. Improved discrimination of molecular subtypes in invasive breast cancer: Comparison of multiple quantitative parameters from breast MRI.
Du S; Gao S; Zhang L; Yang X; Qi X; Li S
Magn Reson Imaging; 2021 Apr; 77():148-158. PubMed ID: 33309922
[TBL] [Abstract][Full Text] [Related]
16. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
[TBL] [Abstract][Full Text] [Related]
17. Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.
Song XL; Kang HK; Jeong GW; Ahn KY; Jeong YY; Kang YJ; Cho HJ; Moon CM
World J Gastroenterol; 2016 Jun; 22(24):5520-31. PubMed ID: 27350730
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
[TBL] [Abstract][Full Text] [Related]
20. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
